A two-way crossover clinical trial to investigate the pharmacokinetics and oral bioavailability and to assess the safety and tolerability of RPL554
Phase of Trial: Phase I
Latest Information Update: 08 Aug 2017
At a glance
- Drugs RPL 554 (Primary)
- Indications Chronic obstructive pulmonary disease; Cystic fibrosis
- Focus Adverse reactions; Pharmacokinetics
- 08 Aug 2017 According to a Verona Pharma media release, dosing in this study is completed and top-line data is expected in the fourth quarter of 2017.
- 05 Jun 2017 According to a Verona Pharma media release, first patient has been enrolled in the study.
- 05 Jun 2017 Status changed from not yet recruiting to recruiting, according to a Verona Pharma media release.